A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome

Kidney Int Rep. 2024 Jul 30;9(10):3067-3069. doi: 10.1016/j.ekir.2024.07.027. eCollection 2024 Oct.

Zhuo-Ran Song^{1

2

3

4

5}, Yang Li^{1

2

3

4

5}, Hong Zhang^{1

2

3

4

5}, Xu-Jie Zhou^{1

2

3

4

5}

¹ Renal Division, Peking University First Hospital, Beijing, China.
² Kidney Genetics Center, Peking University Institute of Nephrology, Beijing, China.
³ Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
⁴ Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education, Peking University, Beijing, China.
⁵ State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.

No abstract available

Keywords: Alport syndrome; ambrisentan; endothelin A receptor antagonist; genetic kidney disease; proteinuria; treatment.